Generated: May 28, 2017
Which drugs does patent 8,470,347 protect, and when does it expire?
|Title:||Self-emulsifying active substance formulation and use of this formulation|
|Abstract:||The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.|
|Inventor(s):||Berndl; Gunther (Herxheim, DE), Breitenbach; Jorg (Mannheim, DE), Heger; Robert (Heidelberg, DE), Stadler; Michael (Neulu.beta.heim, DE), Wilke; Peter (Ludwigshafen, DE), Rosenberg; Jorg (Ellerstadt, DE)|
|Assignee:||AbbVie Deutschland GmbH and Co KG (Wiesbaden, DE)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Compound; Dosage form;|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
|TABLET;ORAL||021906-002||Nov 9, 2007||RX||Yes||No||8,470,347*PED||► Subscribe||Y|
|TABLET;ORAL||021906-001||Oct 28, 2005||RX||Yes||Yes||8,470,347*PED||► Subscribe||Y|
|TABLET;ORAL||022417-001||Feb 10, 2010||AB||RX||Yes||Yes||8,470,347*PED||► Subscribe||Y|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.